The Week Ahead: Hom...
Health Care: Drugs
Protalix BioTherapeutics Inc. (PLX: AMEX)
$5.16 -0.06 | -1.15%
05/17/13 - 04:02 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 52.04M | 27.00M | 35.90M | 81.27M |
| Receivables | 1.41M | 5.21M | 9.24M | 2.14M |
| Inventories | 4.04M | 279.00K | 1.19M | 0.00 |
| Other Current Assets | 3.14M | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 61.17M | 32.49M | 46.33M | 83.41M |
| Property, Plant & Equipment, Gross | 31.10M | 29.42M | 25.04M | 19.23M |
| Accumulated Depreciation & Depletion | 14.79M | 11.15M | 7.59M | 4.70M |
| Property, Plant & Equipment, Net | 16.31M | 18.27M | 17.45M | 14.54M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 1.25M | 1.04M | 942.00K | 724.00K |
| Total Non-Current Assets | 17.56M | 19.31M | 18.40M | 15.26M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 78.73M | 51.80M | 64.73M | 98.67M |
| Accounts Payable | 6.83M | 12.57M | 14.34M | 16.97M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 5.71M | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 25.76M | 18.69M | 18.90M | 21.53M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 56.33M | 59.19M | 57.15M | 61.26M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 56.33M | 59.19M | 57.15M | 61.26M |
| Total Liabilities | 82.08M | 77.88M | 76.05M | 82.79M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -3.36M | -26.08M | -11.32M | 15.88M |
| Common Par | 93.00K | 86.00K | 81.00K | 81.00K |
| Additional Paid In Capital | 180.14M | 145.81M | 124.04M | 122.25M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -183.60M | -171.98M | -135.45M | -106.45M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | -3.36M | -26.08M | -11.32M | 15.88M |
| Total Equity | -3.36M | -26.08M | -11.32M | 15.88M |
| Total Liabilities & Stock Equity | 78.73M | 51.80M | 64.73M | 98.67M |
| Total Common Shares Outstanding | 93.49M | 85.63M | 80.84M | 80.84M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 90.85M | 84.65M | 80.96M | 76.94M |
| Diluted Weighted Shares Outstanding | 90.85M | 84.65M | 80.96M | 76.94M |
| Number of Employees | 266 | 235 | 240 | 182 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with PLX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserSharebuilder
- UserSUPRATRADE HOT STOCKS (BUY ...
- Usergilver Portfolio 1
- UserTop Biotech Short Squeeze P...
- UserEdwin Lee Portfolio 1
Latest PLX Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 04.04.13 | 01:04 pm
- Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112, An Orally-Administered Enzyme Treatment Of Gaucher Disease 04.02.13 | 07:04 am
- UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease 03.18.13 | 02:03 pm
- Protalix BioTherapeutics Receives Approval To Initiate Phase I Study In Gaucher Patients With PRX-112, An Orally-Administered Candidate For The Treatment Of Gaucher Disease 03.07.13 | 08:03 am
- Protalix Announces New Clinical Data On ELELYSO(TM) To Be Presented At The WORLD Symposium 2013 02.13.13 | 07:02 am
- Protalix BioTherapeutics Reviewing Partnering And Other Alternatives 02.05.13 | 11:02 am
- Protalix BioTherapeutics To Present At The 15th Annual BIO CEO & Investor Conference 02.05.13 | 07:02 am
- Protalix BioTherapeutics Announces New Clinical Data On Taliglucerase Alfa To Be Presented At The WORLD Lysosomal Disease Network Symposium 01.31.13 | 07:01 am
- Protalix BioTherapeutics Announces First Patient Treated In Phase I/II Study Of Fabry Patients With PRX-102 12.10.12 | 02:12 am
- 4 Plays Under $10 on the Rise 11.13.12 | 05:11 pm
Press Releases for PLX
- Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO™ (taliglucerase Alfa) For The Treatment Of Gaucher Disease - Business Wire 05.01.12 | 06:05 pm
- FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012 - PR Newswire 12.06.11 | 07:12 am
- Protalix Announces Successful European GMP Audit - PR Newswire 12.01.11 | 02:12 am
- Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease - PR Newswire 11.10.11 | 01:11 am
- Protalix BioTherapeutics To Present At Four Upcoming Conferences - PR Newswire 10.26.11 | 07:10 am
- Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference - PR Newswire 09.21.11 | 07:09 am
- Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference - PR Newswire 09.13.11 | 08:09 am
- Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology - PR Newswire 09.08.11 | 08:09 am
- Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date - PR Newswire 08.17.11 | 07:08 am
- Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial - PR Newswire 08.01.11 | 08:08 am
Partner Headlines for PLX
- Orphan Status Sought for PSTI Drug - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ 08.24.12 | 10:08 pm
- Pluristem-BCRT Alliance Extended - Analyst Blog - NASDAQ 08.22.12 | 11:08 pm
- Pluristem Gets Green Light in India - Analyst Blog - NASDAQ 08.20.12 | 11:08 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- 6 Biotech Stocks With Huge Potential In May - Seeking Alpha 04.11.12 | 08:04 am
- Protalix Reinforces Case For Taliglucerase Alfa; Healthcare Sector Volume Keeps Rising - Seeking Alpha 02.10.12 | 08:02 am
- Company News for December 7, 2011 - Corporate Summary - Zacks 12.07.11 | 09:12 am
- Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point - Seeking Alpha 12.07.11 | 09:12 am
- Morning Market Losers - Benzinga 12.06.11 | 09:12 am
